From palliation to epigenetic therapy in myelofibrosis.

Alessandro Rambaldi, Tiziano Barbui, Giovanni Barosi

Research output: Contribution to journalArticle

Abstract

Myelofibrosis shows a progressive clinical course and usually a poor, lethal prognosis. The molecular pathogenesis of this disease largely remains to be fully understood but the identification of the JAK2V617F mutation in more than half of patients was a major improvement in our understanding of the disease biology and may represent the first biologic marker useful for risk stratification, independently from conventional clinical predictors. After many elusive efforts, new effective treatment strategies are becoming available for this disease. Allogeneic transplantation following reduced-intensity conditioning programs, at least in some patients, may induce not only a hematologic response but also a molecular remission, thus supporting the hope of a possible, definitive eradication of the disease. Moreover, new innovative drugs, targeting either the JAK2V617F mutation or more general oncogenic mechanisms, may provide widely applicable, effective treatments to many patients for whom allogeneic transplantation is not feasible.

Original languageEnglish
Pages (from-to)83-91
Number of pages9
JournalHematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program
Publication statusPublished - 2008

Fingerprint

Primary Myelofibrosis
Epigenomics
Homologous Transplantation
Disease Eradication
Mutation
Drug Delivery Systems
Therapeutics
Biomarkers

ASJC Scopus subject areas

  • Medicine(all)

Cite this

From palliation to epigenetic therapy in myelofibrosis. / Rambaldi, Alessandro; Barbui, Tiziano; Barosi, Giovanni.

In: Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 2008, p. 83-91.

Research output: Contribution to journalArticle

@article{5da25f4630fd4386b542d6c5c1de178a,
title = "From palliation to epigenetic therapy in myelofibrosis.",
abstract = "Myelofibrosis shows a progressive clinical course and usually a poor, lethal prognosis. The molecular pathogenesis of this disease largely remains to be fully understood but the identification of the JAK2V617F mutation in more than half of patients was a major improvement in our understanding of the disease biology and may represent the first biologic marker useful for risk stratification, independently from conventional clinical predictors. After many elusive efforts, new effective treatment strategies are becoming available for this disease. Allogeneic transplantation following reduced-intensity conditioning programs, at least in some patients, may induce not only a hematologic response but also a molecular remission, thus supporting the hope of a possible, definitive eradication of the disease. Moreover, new innovative drugs, targeting either the JAK2V617F mutation or more general oncogenic mechanisms, may provide widely applicable, effective treatments to many patients for whom allogeneic transplantation is not feasible.",
author = "Alessandro Rambaldi and Tiziano Barbui and Giovanni Barosi",
year = "2008",
language = "English",
pages = "83--91",
journal = "Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program",
issn = "1520-4391",
publisher = "American Society of Hematology",

}

TY - JOUR

T1 - From palliation to epigenetic therapy in myelofibrosis.

AU - Rambaldi, Alessandro

AU - Barbui, Tiziano

AU - Barosi, Giovanni

PY - 2008

Y1 - 2008

N2 - Myelofibrosis shows a progressive clinical course and usually a poor, lethal prognosis. The molecular pathogenesis of this disease largely remains to be fully understood but the identification of the JAK2V617F mutation in more than half of patients was a major improvement in our understanding of the disease biology and may represent the first biologic marker useful for risk stratification, independently from conventional clinical predictors. After many elusive efforts, new effective treatment strategies are becoming available for this disease. Allogeneic transplantation following reduced-intensity conditioning programs, at least in some patients, may induce not only a hematologic response but also a molecular remission, thus supporting the hope of a possible, definitive eradication of the disease. Moreover, new innovative drugs, targeting either the JAK2V617F mutation or more general oncogenic mechanisms, may provide widely applicable, effective treatments to many patients for whom allogeneic transplantation is not feasible.

AB - Myelofibrosis shows a progressive clinical course and usually a poor, lethal prognosis. The molecular pathogenesis of this disease largely remains to be fully understood but the identification of the JAK2V617F mutation in more than half of patients was a major improvement in our understanding of the disease biology and may represent the first biologic marker useful for risk stratification, independently from conventional clinical predictors. After many elusive efforts, new effective treatment strategies are becoming available for this disease. Allogeneic transplantation following reduced-intensity conditioning programs, at least in some patients, may induce not only a hematologic response but also a molecular remission, thus supporting the hope of a possible, definitive eradication of the disease. Moreover, new innovative drugs, targeting either the JAK2V617F mutation or more general oncogenic mechanisms, may provide widely applicable, effective treatments to many patients for whom allogeneic transplantation is not feasible.

UR - http://www.scopus.com/inward/record.url?scp=67651149991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651149991&partnerID=8YFLogxK

M3 - Article

C2 - 19074063

AN - SCOPUS:67651149991

SP - 83

EP - 91

JO - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

JF - Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

SN - 1520-4391

ER -